JPWO2019175776A5 - - Google Patents

Claims (7)

A pharmaceutical agent for treating abnormal cell proliferation in a mammal, which comprises the compound or salt according to any one of claims 1 to 29 in a therapeutically effective amount. The drug according to claim 33, wherein the compound or salt is a component of an antibody pharmaceutical complex. 33. The pharmaceutical according to claim 33, wherein the compound or salt is a component of a particle-based delivery system. 33. The pharmaceutical art according to claim 33, wherein the abnormal cell proliferation is cancer. Cancers include lung cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, skin or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, stomach cancer, colon cancer, breast cancer, uterine cancer, Oviductal cancer, endometrial cancer, cervical cancer, vaginal cancer, genital cancer, Hodgkin's disease, esophageal cancer, small intestinal cancer, endocrine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urinary tract cancer, penis cancer , Prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney or urinary tract cancer, renal cell cancer, renal meng cancer, central nervous system (CNS) tumor, central nervous system primary lymphoma, spinal axis tumor, 36. The apparatus of claim 36, which is a brain stem glioma or pituitary adenoma . A pharmaceutical agent for upregulating the activity of STING in a mammal, which comprises an effective amount of the compound or salt according to any one of claims 1 to 29. A pharmaceutical agent for increasing the level of interferon β in a mammal, which comprises an effective amount of the compound or salt according to any one of claims 1 to 29.